LAS VEGAS – The U.S. FDA has said it is looking to help those interested in developing digital health tools, and that commitment took center stage this week during the Digital Health Summit, part of CES 2020. Amy Abernethy, principal deputy commissioner at the FDA, gave an overview of the agency’s thinking on the topic, providing the perspective of someone who came from outside the regulatory world.
LAS VEGAS – Over the past three years or so, voice technology has been on the rise, with hospitals looking to leverage it to help patients. Tech companies have taken notice; for example, Amazon assisted with technology to make voice skills HIPAA-compliant, with six skills unveiled as part of that effort.
ORLANDO, Fla. – Two preclinical presentations at the 61st American Society of Hematology (ASH) annual meeting could pave the way for using hematopoietic stem cell transplants (HSCT) in patients who are currently too sick to tolerate the procedure, as well as in indications where its toxicities preclude its use.
There's a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month. They contribute to tumorigenesis, resistance and tumor heterogeneity. But they are also often specific to tumor cells but not normal cells and "some," he said, "are actionable targets."
Francis Collins, director of the U.S. NIH, said in a public forum that his agency is "really bullish" about precision medicine. Precision medicine requires mounds of data to be viable; however, the necessary data may soon be available. Collins said the NIH's All of Us research program has drawn the interest of more than 300,000 willing participants to date, adding that the target enrollment of 1 million should be accomplished before the end of 2022.